## Supplementary Table 2. Primary and secondary efficacy endpoints at week 96 – per-protocol set

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **HBeAg-positive patients** | | | | **HBeAg-negative patients** | | | |
| **TMF 25 mg**  **(n = 458)** | **TDF 300 mg**  **(n = 229)** | **Difference**  **(95% CI)** | ***p*-value** | **TMF 25 mg**  **(n = 174)** | **TDF 300 mg**  **(n = 84)** | **Difference**  **(95% CI)** | ***p*-value** |
| HBV DNA < 20 IU/mL | 325/458 (71.0%) | 163/229 (71.2%) | -0.0  (-6.90,6.86) | 0.995 | 162/174 (93.1%) | 79/84 (94.0%) | -1.0  (-7.32,5.41) | 0.773 |
| HBV DNA < 29 IU/mL | 344/458 (75.1%) | 177/229 (77.3%) | -2.1  (-8.51,4.41) | 0.540 | 163/174 (93.7%) | 79/84 (94.0%) | -0.4  (-6.71,5.90) | 0.900 |
| HBV DNA < 69 IU/mL | 382/458 (83.4%) | 193/229 (84.3%) | -0.8  (-6.53,4.96) | 0.792 | 166/174 (95.4%) | 79/84 (94.0%) | 1.3  (-4.72,7.35) | 0.655 |
| HBeAg lossa | 120/420 (28.6%) | 57/213 (26.8%) | 2.1  (-5.01,9.30) | 0.562 | - | - | - | - |
| HBeAg seroconversionb | 60/364 (16.5%) | 25/177 (14.1%) | 2.5  (-3.90,8.82) | 0.461 | - | - | - | - |
| HBsAg lossc | 1/458 (0.2%) | 1/229 (0.4%) | - | - | 2/174 (1.1%) | 0 (0.00) | NC | NC |
| Mean ALT change from baseline (SD) | -114.60 (114.87) | -100.57 (103.20) | -4.44  (-7.90,-0.97) | 0.012 | -96.71 (107.12) | -85.27 (112.13) | -0.69  (-4.50,3.12) | 0.721 |
| ALT normalization rated | 326/422 (77.3%) | 141/209 (67.5%) | 9.7  (2.18,17.22) | 0.009 | 121/162 (74.7%) | 54/75 (72.0%) | 2.6  (-9.84,15.01) | 0.677 |
| Meane FIB-4 score change from baseline (SD) | -0.49 (0.89) | -0.51 (0.91) | -0.09  (-0.17,0.00) | 0.044 | -0.77 (1.40) | -0.37 (0.88) | -0.09  (-0.27,0.08) | 0.286 |
| Meane LSM value change from baseline (SD) | -3.74 (5.32) | -4.79 (6.14) | 0.42  (-0.02,0.86) | 0.060 | -3.08 (6.07) | -3.38 (4.25) | 0.55  (-0.32,1.41) | 0.212 |
| Data are *n*/N or *n*/*n* (%) unless otherwise stated. AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; PPS, per-protocol set.  aAmong patients who were seropositive for HBeAg; bAmong patients who were seropositive for HBeAg and negative for anti-HBe at baseline; cAmong patients who were seropositive for HBsAg; dThe upper limit of normal is 35 U/L for male and 25 U/L for female; eLeast squares mean. | | | | | | | | |